NCT07379333

A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 118 (estimated)
• Sponsor: Hanmi Pharmaceutical Company Limited · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

A multicenter, randomized, double-blind, phase 3 study to evaluate efficacy and safety of HM11260C in patients with type 2 diabetes mellitus inadequately controlled with metformin and dapagliflozin

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	HM11260C	Test drug
DRUG	Placebo	Placebo drug

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-11-01
• Completion: 2028-01-01
• First posted: 2026-01-30
• Last updated: 2026-01-30

Locations

1 site across 1 country: South Korea